Disvestment of entire stake in Material subsidiary Convert outstanding debt extended to Material subsidiary into equity shares Appointment of Additional independent non-executive director

Kilitch Drugs (India) Ltd. Ki 22” October, 2026 National Stock Exchange of India, BSE Limited, Listing Department, Department of Corporate Services - Listing, Bandra Kurla Complex Phiroze Jeejebhoy Towers, Bandra East, Dalal Street, Mumbai - 400 051 Mumbai- 400 001 Dear Sir, Sub.: Outcome of the Board Meeting Pursuant to Regulations 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “LODR”), we would like to inform you that the Board of Directors (the “Board’’), at their meeting held today i.e. 224 October, 2026, have considered and approved the following; 1. Sell, transfer and otherwise dispose of its entire shareholding in Kilitch Estro Biotech PLC, a company incorporated under the laws of the Federal Democratic Republic of Ethiopia, (including any additional equity shares acquired by the Company pursuant to the conversion of its outstanding debt including service cost into equity shares of Kilitch Estro Biotech PLC prior to completion of the divestment), to HarmeeCare Pharmaceuticals, a state-owned public enterprise established under the laws of the Oromia Regional State of Ethiopia. The aggregate consideration payable by the buyer for the sale of 100% (hundred percent) shareholding of KEB (and to enable KEB to discharge its existing debts and liabilities) shall be USD 14,000,000 (United States Dollars Fourteen Million) out of which, the consideration due to the Company shall be USD 12,855,000 (United States Dollars Twelve Million Eight Hundred and Fifty Five Thousand). 2. To convert the entire outstanding debt including service cost aggregating upto INR [57.00 Crores] (extended by the Company to Kilitch Estro Biotech PLC, a company incorporated under the laws of the Federal Democratic Republic of Ethiopia and a material subsidiary of the Company as per applicable laws (“KEB”) into equity shares of KEB, in compliance with FEMA and other applicable laws including reporting requirements and other compliances (“Conversion”). The details required with respect to the transaction specified in Point No. | and Point No. 2 under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed as Annexure A and Annexure B. GNI. 434852003 WHO CERTIFIED Corporate office : 37/39, Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai - 400 088. « Tel.: +91-22-6121 4100 « Fax : +91-22-6703 1658 Registered Office & Manufacturing unit : C-301/2, M.1.D.C., T.T.C. Industrial Area, Pawane Village, Navi Mumbai - 400 705. Maharashtra. o CIN: L24239MH1992PLC066718 Tel.: +91-22-6299 6300 « Fax : +91-22-2768 0912 » E-mail : info@kilitch.com « Website : www.kilitch.com Kilitch Drugs (India) Ltd. KI 3. Appointment of Dr. Milind Kishor Madha ni (DIN:02378529) as an Additional Director (Non-executive, Independent) for a period of 5 years with effect from 23" October, 2026, subject to member’s approval at ensuing EGM. Brief Profile of Dr. Milind Kishor Madhani is enclosed herewith as annexure - C 4. Appointment of Mr. Gautam Rajan (DIN:00060730) as an Additional Director (Non- executive, Independent) for a period of 5 years with effect from 23" October, 2026, subject to member’s approval at ensuing EGM. Brief Profile of Mr. Gautam Rajan is enclosed herewith as annexure — D 5. Notice of Extra Ordinary General Meeting (“EGM”) of the Company to be convened and held on Monday, 16" October, 2026 at 9:00 am through video conferencing and other audio visual means only 6. Appointment of Mr. Deep Shukla and Associates, Practicing Company Secretary as Scrutinizer to conduct the entire voting process at EGM of the Company (including e- voting) and to submit the Report for declaration of the results thereof The Board Meeting commenced at 17:30 hours IST and concluded at 20.05 hours IST. We request you to kindly take note of the same and acknowledgement the receipt For Kilitch Drugs (India) Limited Mukund Mehta Managing Director ; NDIA 9004:2008 ata 13485:2003 WHO CERTIFIED / harmacy of the World Corporate office : 37/39, Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai - 400 088. « Tel.: +91-22-6121 4100 » Fax : +91-22-6703 1658 Registered Office & Manufacturing unit : C-301/2, M.1.D.C., T.T.C. Industrial Area, Pawane Village, Navi Mumbai - 400 705. Maharashtra. ¢ CIN: L24239MH1992PLC066718 e Tel.: +91-22-6299 6300 » Fax : +91-22-2768 0912 « E-mail : info@kilitch.com » Website : www.kilitch.com tats .tec Kilitch Drugs (India) Ltd. (Annexure A) Details with respect divestment in Kilitch Estro Biotech PLC, a material subsidiary of the Company as required under Regulation 30 Read with Schedule III of the LODR and SEBJ Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Sr. Particulars Details 1. | The amount and percentage of the turnover or revenue or income and net Particulars Consolidat | % worth contributed by Kilitch Estro ed Biotech PLC during the last financial Turnover | 47.57 | 235.47 20.20 year. FY 2025- % (amount in crores) Net Worth | (8.43) | 267.87 (3.14) as; on 31” % March, 2026 (amount in Crores) 2. | Date on which the agreement for sale Binding minutes of meeting between parties has been entered into have been signed on 22" October, 2026 which sets out the key terms of the divestment. Share purchase agreement and other transaction documents will be signed in due course. 3. | The expected date of completion of 31/01/2027 sale/disposal. 4. | Consideration due from — such USD 1,28,55,000 sale/disposal. 5. | Brief details of buyers and whether HarmeeCare Pharmaceuticals, a state-owned any of the buyers belong to the public enterprise established under the laws of promoter/ promoter group/group the Oromia Regional State of the Federal companies. If yes, details thereof. Democratic Republic of Ethiopia. The buyer does not belong to the promoter/promoter group/ group companies. 6. | Whether the transaction would fall No, the transaction does not fall within related within related party transactions? If SONIA 139 40 80 51 :: 22 00 00 38 WHO CERTIFIED _» Pharmacy of the World Corporate office : 37/39, Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai - 400 088. e Tel.: +91-22-6121 4100 « Fax : +91-22-6703 1658 Registered Office & Manufacturing unit : C-301/2, M.1.D.C., T.T.C. Industrial Area, Pawane Village, Navi Mumbai - 400 705. Maharashtra. e CIN: L24239MH1992PLC066718 « Tel.: +91-22-6299 6300 « Fax : +91-22-2768 0912 » E-mail : info@kilitch.com » Website : www.kilitch.com Kilitch Drugs (India) Ltd. yes, whether the same is done at “arm’s length”. Whether the sale, lease or disposal of Yes, consent of members of the company is the undertaking is outside Scheme of being sought under Regulation 37A of LODR Arrangement? If yes, details of the Regulations and other applicable legal same including compliance with provisions and the transaction is subject to regulation 37A of LODR Regulations. receipt of such approval of members. Additionally, in case of a slump sale, NA indicative disclosures provided for amalgamation/merger, shall —_be disclosed by the listed entity with respect to such slump sale. Others NA (Annexure B) Details with respect to acquisition of additional equity shares pursuant to the conversion of the Company’s outstanding debt including service cost aggregating upto INR 57.00 Crores extended to Kilitch Estro Biotech PLC (“KEB”), a material subsidiary of the Company, into equity shares of KEB as required under Regulation 30 read with Schedule III of the LODR and SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3 762/2026 dated January 30, 2026. Particulars Details Name of the target entity, details in Kilitch Estro Biotech PLC brief such as size, turnover etc. Size/Turnover: 47.57 Crores Whether the acquisition would fall Kilitch Estro Biotech PLC, being a material within related party transaction( [Showing first 8,000 characters — download PDF for full document]